Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.

Konishi S, Hatakeyama S, Numakura K, Narita S, Inoue T, Saito M, Tokui N, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Narita S, Kawaguchi T, Habuchi T, Ohyama C.

Clin Genitourin Cancer. 2019 Jul 20. pii: S1558-7673(19)30222-8. doi: 10.1016/j.clgc.2019.07.006. [Epub ahead of print]

PMID:
31416753
2.

Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis.

Numakura K, Horikawa Y, Kamada S, Koizumi A, Nara T, Chiba S, Kanda S, Saito M, Narita S, Inoue T, Shimoda N, Habuchi T.

Mol Clin Oncol. 2019 Sep;11(3):320-324. doi: 10.3892/mco.2019.1887. Epub 2019 Jun 25.

3.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G.

Int J Clin Oncol. 2019 Sep;24(9):1089-1098. doi: 10.1007/s10147-019-01450-w. Epub 2019 Jun 19.

PMID:
31218529
4.

Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression.

Narita S, Nara T, Sato H, Koizumi A, Huang M, Inoue T, Habuchi T.

J Clin Med. 2019 Apr 30;8(5). pii: E597. doi: 10.3390/jcm8050597. Review.

5.

Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.

Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T, Satoh S, Nanjo H, Tsuchiya N, Mitsuzuka K, Koie T, Kawamura S, Ohyama C, Tochigi T, Arai Y, Habuchi T.

Clin Genitourin Cancer. 2019 Feb;17(1):e113-e122. doi: 10.1016/j.clgc.2018.09.019. Epub 2018 Sep 27.

PMID:
30391137
6.

Can single positive core prostate cancer at biopsy be considered a low-risk disease?

Yamamoto H, Koie T, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Kawamura S, Kato T, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C.

Int Urol Nephrol. 2018 Oct;50(10):1829-1833. doi: 10.1007/s11255-018-1966-y. Epub 2018 Aug 20.

PMID:
30128924
7.

Incidence and location of positive surgical margin among open, laparoscopic and robot-assisted radical prostatectomy in prostate cancer patients: a single institutional analysis.

Koizumi A, Narita S, Nara T, Takayama K, Kanda S, Numakura K, Tsuruta H, Maeno A, Huang M, Saito M, Inoue T, Tsuchiya N, Satoh S, Nanjo H, Habuchi T.

Jpn J Clin Oncol. 2018 Aug 1;48(8):765-770. doi: 10.1093/jjco/hyy092.

PMID:
29931077
8.

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.

Numakura K, Fujiyama N, Takahashi M, Igarashi R, Tsuruta H, Maeno A, Huang M, Saito M, Narita S, Inoue T, Satoh S, Tsuchiya N, Niioka T, Miura M, Habuchi T.

Oncotarget. 2018 May 18;9(38):25277-25284. doi: 10.18632/oncotarget.25423. eCollection 2018 May 18.

9.

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.

Sato H, Narita S, Tsuchiya N, Koizumi A, Nara T, Kanda S, Numakura K, Tsuruta H, Maeno A, Saito M, Inoue T, Satoh S, Nomura K, Habuchi T.

BMC Urol. 2018 May 8;18(1):32. doi: 10.1186/s12894-018-0353-4.

10.

Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.

Komine N, Satoh S, Saito M, Numakura K, Inoue T, Tsuruta H, Narita S, Komatsuda A, Nanjo H, Kagaya H, Niioka T, Miura M, Mitobe Y, Habuchi T.

Int Immunopharmacol. 2018 May;58:57-63. doi: 10.1016/j.intimp.2018.03.004. Epub 2018 Mar 15.

PMID:
29550576
11.

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.

Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.

Int J Mol Sci. 2018 Mar 16;19(3). pii: E882. doi: 10.3390/ijms19030882.

12.

A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.

Inoue T, Miyazaki J, Ichioka D, Narita S, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Matsui Y, Fujie K, Habuchi T, Nishiyama H.

BMC Cancer. 2018 Mar 14;18(1):290. doi: 10.1186/s12885-018-4186-z.

13.

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.

Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.

Med Oncol. 2018 Mar 9;35(4):51. doi: 10.1007/s12032-018-1113-8.

PMID:
29524031
14.

Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production.

Huang M, Narita S, Inoue T, Koizumi A, Saito M, Tsuruta H, Numakura K, Satoh S, Nanjo H, Sasaki T, Habuchi T.

Oncotarget. 2017 Dec 4;8(67):111780-111794. doi: 10.18632/oncotarget.22908. eCollection 2017 Dec 19.

15.

Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Matsumoto T, Hatakeyama S, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Yamashita S, Narita T, Koie T, Kawamura S, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C.

Med Oncol. 2017 Oct 31;34(12):190. doi: 10.1007/s12032-017-1050-y.

PMID:
29090390
16.

Quantification of Interstitial Fibrosis in Renal Allografts and Clinical Correlates of Long-Term Graft Function.

Nara M, Komatsuda A, Numakura K, Saito M, Inoue T, Niioka T, Miura M, Mitobe Y, Okuyama S, Takahashi N, Habuchi T, Satoh S.

Am J Nephrol. 2017;46(3):187-194. doi: 10.1159/000479983. Epub 2017 Aug 22.

PMID:
28848141
17.

An In Vitro Study of a New Device: Evaluation of Novel Wide-Angle Lens Flexible Cystoscope Using Phantom Bladder Model.

Yamaguchi K, Inoue T, Habuchi T, Inokuchi J, Yokomizo A, Eto M, Kanayama HO.

J Endourol. 2017 Oct;31(10):1073-1078. doi: 10.1089/end.2017.0371.

PMID:
28726499
18.

Host-related Risk Factors for Adherent Perinephric Fat in Healthy Individuals Undergoing Laparoscopic Living-donor Nephrectomy.

Narita S, Kumazawa T, Tsuchiya N, Mingguo H, Saito M, Inoue T, Tsuruta H, Numakura K, Maeno A, Nanjo H, Satoh S, Habuchi T.

Surg Laparosc Endosc Percutan Tech. 2017 Aug;27(4):e69-e73. doi: 10.1097/SLE.0000000000000433.

19.

Inverse relationship between insulin receptor expression and progression in renal cell carcinoma.

Takahashi M, Inoue T, Huang M, Numakura K, Tsuruta H, Saito M, Maeno A, Nakamura E, Narita S, Tsuchiya N, Habuchi T.

Oncol Rep. 2017 May;37(5):2929-2941. doi: 10.3892/or.2017.5552. Epub 2017 Apr 5.

PMID:
28393204
20.

Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.

Takayama K, Inoue T, Narita S, Maita S, Huang M, Numakura K, Tsuruta H, Saito M, Maeno A, Satoh S, Tsuchiya N, Habuchi T.

Cancer Lett. 2017 Jul 1;397:103-110. doi: 10.1016/j.canlet.2017.03.034. Epub 2017 Mar 31.

PMID:
28373003

Supplemental Content

Loading ...
Support Center